Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutated NSCLC”

716 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 716 results

Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Large-scale testing (Phase 3)UnknownNCT03203590
What this trial is testing

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

Who this might be right for
2-year Disease-Free Survival
Sun Yat-sen University 590
Large-scale testing (Phase 3)UnknownNCT02001896
What this trial is testing

Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Xinjiang Medical University 60
Large-scale testing (Phase 3)Not Yet RecruitingNCT07416994
What this trial is testing

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 440
Large-scale testing (Phase 3)Study completedNCT02864251
What this trial is testing

Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Who this might be right for
Non-Small-Cell Lung Carcinoma
Bristol-Myers Squibb 367
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Not applicableLooking for participantsNCT05997719
What this trial is testing

Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 150
Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Testing effectiveness (Phase 2)Study completedNCT01588145
What this trial is testing

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 273
Not applicableLooking for participantsNCT06418412
What this trial is testing

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

Who this might be right for
Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
National Cancer Centre, Singapore 600
Testing effectiveness (Phase 2)Study completedNCT03434418
What this trial is testing

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Duke University 17
Testing effectiveness (Phase 2)Looking for participantsNCT05334277
What this trial is testing

Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 280
Not applicableStudy completedNCT02623257
What this trial is testing

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Who this might be right for
Non-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic
First People's Hospital of Hangzhou 1,055
Not applicableActive Not RecruitingNCT07491211
What this trial is testing

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Brain Metastases From Non-small Cell Lung Cancer (NSCLC)Osimertinib+1 more
Fudan University 300
Early research (Phase 1)Study completedNCT00993499
What this trial is testing

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06585644
What this trial is testing

A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Who this might be right for
Lung Cancer (NSCLC)
Shanghai Pulmonary Hospital, Shanghai, China 44
Testing effectiveness (Phase 2)Study completedNCT02616393
What this trial is testing

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Who this might be right for
Non-Small Cell Lung CancerLeptomeningeal MetastasesBrain Metastases
Kadmon Corporation, LLC 36
Testing effectiveness (Phase 2)Study completedNCT00997334
What this trial is testing

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Who this might be right for
Non-small Cell Lung Cancer
David M. Jackman, MD 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187
What this trial is testing

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Who this might be right for
Non-squamous NSCLC
Shanghai Chest Hospital 54
Load More Results